Strength Archives - World Asthma Foundation

February 15, 2016

TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

Condition: Asthma
Interventions: Drug: CHF 5993 100/6/12.5 µg; Drug: CHF 1535 100/6 µg
Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting – verified February 2016

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

February 9, 2016

TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)

Condition: Asthma
Interventions: Drug: CHF 5993 200/6/12.5 µg; Drug: CHF 1535 200/6 µg; Drug: CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg
Sponsor: Chiesi Farmaceutici S.p.A.
Not yet recruiting – verified February 2016

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

May 9, 2015

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Condition: Asthma
Interventions: Drug: Treatment A: Fp MDPI; Drug: Treatment B: FS MDPI; Drug: Treatment C Flovent; Drug: Treatment D: Advair
Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.
Not yet recruiting – verified May 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days